Amylyx Pharmaceuticals (AMLX) TD Cowen 46th Annual Health Care Conference summary

Strategic outlook and key milestones

• 2026 is expected to be transformative, with top-line results from the LUCIDITY phase III trial for avexitide in PBH anticipated in Q3 2026.

• NDA submission is planned following positive results, with commercialization targeted for 2027.

• Commercial preparations and NDA work are underway ahead of trial results.

• Cash runway extends into 2028, supporting ongoing development and launch plans.

Clinical development and pipeline updates

• LUCIDITY phase III trial for avexitide has completed screening and expects full enrollment this month.

• Avexitide has shown significant reductions in hypoglycemic events in prior studies, supporting FDA Breakthrough Therapy designation.

• Additional pipeline assets include AMX0114 for ALS (dose-escalating study ongoing) and AMX0035 for Wolfram syndrome.

• A long-acting GLP-1 receptor antagonist is in IND-enabling studies, aiming for less frequent dosing.

Market landscape and unmet need

• PBH affects about 160,000 people in the U.S., with no approved treatments; current management relies on medical nutrition therapy.

• Bariatric surgery rates remain robust despite GLP-1 agonist uptake, and PBH is a lifelong condition.

• PBH patients experience frequent, severe hypoglycemic events impacting daily life and safety.